NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

NewcelX Ltd. (NCEL) Stock Analysis

NewcelX Ltd. (NCEL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NCEL

$3.35

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NCEL with… →

NCEL Key Statistics

As of Sep 4, 2026
Trading
Open
$3.37
Previous Close
$3.35
Day's Range
3.24–3.37
52-Week Range
1.83–24.60
Volume
1.40K
Valuation
Market Cap
$19.35M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.16
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.30M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.78M
1-Year Return
−83.17%
Dividend and dates
Avg Volume
20.34K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NCEL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+76.32%
2025−91.00%
2024−91.06%
2023−54.26%
2022+16.22%
2021−61.59%

As of September 4, 2026.

NCEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.30M—
2024$0.00−$7.20M—
2023$0.00−$3.33M—
2022$0.00−$6.45M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$2.47M−$8.30M—
2024$0.00$0.00−$1.80M−$7.20M—
2023$0.00$0.00−$3.02M−$3.33M—
2022$0.00$0.00−$6.25M−$6.45M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NCEL Valuation vs Biotechnology Median

Median of 656 stocks
MetricNCELBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

NewcelX Ltd. (NCEL) is capitalised at $19.35M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 9.

The 52-week range on file runs from $1.83 to $24.60. The most recent close on file for NCEL is $3.35, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 83.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $8.30M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.16.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Annualized volatility over the trailing 5 years is 125.38%. Over the trailing twelve months the price has returned −83.17%. Measured over 5 years, that is −68.38% a year compounded.

Growth & Income

No dividend is on file for NCEL.

The strongest complete calendar year on file is 2022 at +16.22%; the weakest is 2024 at −91.06%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is +76.32%.

Peer Comparison

NewcelX Ltd. (NCEL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NewcelX Ltd. NCEL $19.35M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. NewcelX Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NewcelX Ltd.

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.

Visit website →